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Interleukin (IL)-2 has been extensively examined to promote clinical Tand natural killer (NK) cell responses.
Regulatory T cells (Tregs) have been shown to regulate many aspects of the immune system, including NK
cell–mediated responses. We have demonstrated that in vivo administration of IL-2 led to activation and ex-
pansion of both NK cells and immunosuppressive Tregs. Therefore, we attempted to augment NK cell an-
titumor effects by concurrently depleting Tregs using anti-CD25. Increased NK cell activation by IL-2 was
found to be correlated with an increase in classical, short-term NK cell in vitro killing assays regardless of
the depletion of Tregs. But when splenocytes of the treated mice were used in long-term tumor outgrowth
experiments, we observed that prior depletion of Tregs from IL-2 administration led to improved antitumor
effects compared with either treatment alone. Importantly, these in vitro data are correlated with subse-
quent in vivo survival of leukemia-bearing mice, in which co-treatment of IL-2 with anti-CD25 led to signif-
icantly improved survival compared with mice treated with either IL-2 alone or with Treg depletion. Prior
depletion of NK1.11 cells, but not of CD81 cells, completely abrogated all antitumor effects mediated by
IL-2 and anti-CD25 combination therapy. These findings demonstrate that superior NK cell–mediated anti-
leukemic effects can be achieved with IL-2 administration and concurrent depletion of CD251 cells.
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Natural killer (NK) cells are members of the innate
immune system and are known tomediate major histo-
compatibility complex (MHC)-unrestricted cytotoxic-
ity against virally infected and neoplastic cells [1,2].
Along with their ability to kill target cells directly,
NK cells also are known to be potent immune modu-
lators with the ability to produce abundant cytokines
capable of altering immune responses [2,3]. NK cells
can promote T helper type-1 (Th1) responses [2,4,5]
and can participate in dendritic cell (DC) maturation
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and tumor-specific memory T cells against various
tumors [7-9]. Previous studies have demonstrated the
broad range of methods by which NK cells can control
immune responses, but none has adequately explained
how NK cell function is modulated by other cells.
CD41CD251 regulatory T cells (Tregs) are criti-
cal immunomodulatory cells that are responsible for
maintaining immune tolerance [10]. Tregs make up
approximately 10% of the entire CD41 T cell pool.
They exclusively express the transcription factor
Foxp3 and are known to prevent organ-specific auto-
immune diseases [10]. The role of Tregs has been
demonstrated in tolerance during infections [11] and
in allogeneic transplantation [12].
The inhibition ofNK cells by Tregs has been dem-
onstrated previously. Recent studies demonstrated
that adoptive transfer of Tregs into C57BL/6 athymic
mice resulted in a down-regulation of NKG2D onNK
cells [13]. This transfer of Tregs was correlated with a
significant increase in lung metastases of the NKG2D-
sensitive tumor cell line B16-Rae, suggesting that
Tregs are capable of suppressing the clearance of
NKG2D-ligand expressing cells. Subsequent studies
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NK cells in short-term killing assays can be inhibited
by the addition of purified Tregs [14]. This inhibition
works against Rae-1–transfected cell lines but not
non–Rae1-transfected control tumor cells. These
investigators also demonstrated that treatment of
B16-Rae1–bearing mice with anti-CD25 led to
decreased lung metastases [14]. The treatment of
mice injected with nontransfected cells produced no
difference in the number of lung metastases. In these
studies, only tumor cell lines transfected with ligands
to the NKG2D receptor were affected by the manipu-
lation of Tregs.
We recently demonstrated that Tregs affect NK
cell function in a murine bone marrow allograft trans-
plant model in which Tregs inhibit NK cell–mediated
rejection of bone marrow allografts [15]. These studies
further support the unique link between NK cells and
Tregs and suggest that future studies designed to en-
hance NK cell function should consider removing
Tregs as part of the therapeutic regimen.
Many immunotherapies currently explored for
treating leukemia revolve around NK cell activation.
NK cells are typically activated with Th1-inducing cy-
tokines (eg, IL-2, IL-12, or IL-18) or with nucleotide
analogues (eg, poly I:C, CpGs) that engage Toll-like
receptors (TLRs). Historically, IL-2 stimulation was
the primarymethod through which humanNK cell ac-
tivation was accomplished, with mixed clinical results
[16-18]. But some studies have demonstrated that
this cytokine also can be a potent activator of Tregs
both in vivo and in vitro [10]. In the present work,
we demonstrated that some of the important immu-
nostimulatory functions of IL-2 are lost through the
activation of Tregs and that concurrent Treg cell de-
pletion allows for more thorough NK cell activation,
increasing the antitumor potential of NK cells.
MATERIALS AND METHODS
Mice
C57BL/6 mice were purchased from the Animal
Production Area, National Cancer Institute (NCI),
Frederick, MD. The female mice were aged 2 to 4
months at the start of the experiments. The animals
were maintained under specific pathogen-free condi-
tions at the University of Nevada Reno animal facility.
Animal care was provided in accordance with the pro-
cedures outlined by the National Institutes of Health.
The animal studies were performed at the University
of Nevada Reno animal facility according to approved
protocols and in accordance with the Animal Care and
Use Committee.
Reagents
Recombinant human IL-2 (TECIN [teceleukin])
was provided by the NCI. Anti-CD25 (clonePC61.5.3) and anti-NK1.1 (PK136) were grown by
the National Cell Culture Center (Minneapolis,
MN). Purified rat IgG was purchased from Jackson
ImmunoResearch Laboratories (West Grove, PA).
The rat antibody to mouse CD8 (clone YTS169.4)
was produced in ascites. The antibody concentration
was 4.3 mg/mL, and the endotoxin level was 3.6 endo-
toxin units/mg antibody.
Cytotoxicity Assays
Yac-1 tumor cells were labeled with Na2
51CrO4
(PerkinElmer, Waltham, MA) and used in a standard
4-hour 51Cr-release assay as described previously
[19]. For chromium release assays, 2000 51Cr-labeled
Yac-1 target cells per well were used. The percent lysis
was calculated as follows: [(experimental lysis - sponta-
neous lysis)/(maximal lysis - spontaneous lysis)] 100.
Each sample was analyzed in triplicate. These experi-
ments were performed 3 times with similar results.
Tumor Outgrowth Assay
Spleens from mice undergoing IL-2 therapy (2 
105 IU IL-2 i.p. on days 1, 3, 5, and 7) and anti-
CD25 therapy (1 mg anti-CD25 i.p. on days 1, 4,
and 7) were removed on day 8, processed into a single
cell suspension, and added to 96-well culture plates at
indicated effector to target (E:T) ratios in RF10 com-
plete media containing 1000 IU/mL IL-2 (Roche,
Basel, Switzerland). Target cells were then added at
1000 targets/well in RF10 complete media containing
1000 IU/mL IL-2. For some control wells, tumor cells
were left out, and instead a medium containing IL-2
alone was added to measure the proliferation of effec-
tor cells alone. After 4 days, 10 mLof the cell milieu was
passed into new wells containing 90 mL of fresh RF10
complete media but lacking IL-2. In some experi-
ments, the passage occurred a second time after an-
other 4 days. Three days after passage (day 7), the
cells were pulsed with 3H-thymidine (1 mCi per well)
(Amersham Pharmacia Life Sciences, Buckingham-
shire, UK), 16 to 18 hours before being harvested
and counted in the presence of scintillation fluid on
aWallac b-plate reader (PerkinElmer). In experiments
designed to determine the mechanism of NK cell cyto-
toxicity against C1498, wild-type or perforin knockout
(pfp-/-) splenocytes were depleted of T cells by anti-
Thy1.2 and rabbit complement and incubated in com-
plete media containing 1000 IU/mL IL-2 for 6 days.
Activated NK cells were then added to 96-well culture
plates at the indicated E:T ratios in media containing
1000 IU/mL IL-2. C1498 target cells were added as
described earlier. After 4 days, cell proliferation was
determined using an MTT Cell Proliferation Kit
(Roche). Tumor outgrowth was determined by sub-
tracting the absorbance values of effectors alone from
wells containing both tumor and effector cells at
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point were analyzed.
Flow Cytometry
Splenocytes from C57BL/6 were prepared at 2 
107 cells/mL in staining buffer (PBS with 1% FBS).
106 cells were labeled with FITC anti-CD25 (7D4),
R-PE anti-CD25 (PC61), PE-cyanine 5 (PC5) anti-
CD4 (GK1.5), PC5 anti-CD3 (145-2C11), FITC or
PE anti-NK1.1 (PK136), biotinylated anti-CD122
(TM-b1) plus PC7-streptavidin (all from eBiosciences;
San Diego, CA), or Fc block (anti-CD16; BD Biosci-
ences, San Jose, CA) and labeled for 15 minutes at
4C. For Foxp3 analysis, intracellular staining was per-
formed using the Foxp3 Kit (eBiosciences). The 2
clones of anti-CD25 antibody were used because
they recognize noncompeting epitopes, allowing us
to examine CD251 cells after in vivo treatment with
PC61 antibody. Phenotype analysis was performed 4
times. Cell counts were determined by percent expres-
sion of light-scattered cells by cell counts as deter-
mined using a Coulter Z1 particle counter (Beckman
Coulter; Fullerton, CA). For granzyme B (GzmB)
analysis, surface-labeled cells were incubated with an
Intraprep Kit (Beckman Coulter) and labeled with
PE anti-human GzmB (GB12), which also reacts
with mouse Gzmb, or PE mouse IgG1 control anti-
bodies (Invitrogen; Carlsbad, CA). GzmB analysis
was performed twice. All flow cytometry was per-
formed with a FACSCAN flow cytometer using Cell-
Quest software (BDBiosciences) or a 4-color Beckman
Coulter XL/MCL using System II software. List mode
flow cytometric data files were analyzed with FlowJo
(Tree Star, Ashland, OR).
Survival Studies
The C57BL/6 mice were injected with 2  105
C1498 leukemia cells i.v. on day 0. Groups of 8 mice
were treated with 2  105 IU IL-2 i.p. on days 1, 3,
5, and 7; 1 mg anti-CD25, PC61.5.3 i.p. on days 1,
4, and 7; or a combination of the two. In some exper-
iments, NK cells were depleted with 500 mg anti-
NK1.1 (clone: PK136) or 300 mg anti-CD8 antibody
(clone:YTS169.4) on days 1 and 5, as described previ-
ously [15]. The mice were monitored for survival and
euthanized if they exhibited morbidity. Each experi-
ment was performed twice.
Statistical Analysis
Statistical analysis was performed using Graphpad
Prism 4 software (Graphpad, El Camino, CA). Student
t test, Fisher‘s exact test, 1-way analysis of variance
(ANOVA), 2-way ANOVA, or the log-rank test was
used where appropriate. A P value\ .05 was consid-
ered statistically significant. Data are given as mean
6 standard deviation unless specified otherwise.RESULTS
IL-2 Administration Promoted NK Cell
Numbers, Function, and Antitumor Effects in
Vivo
Previous studies have demonstrated a potential an-
titumor effect of IL-2 in cancer, especially renal cancer
andmelanoma [20,21].We first examined the effects of
IL-2 on NK cell antitumor effects ex vivo. C57BL/6
mice were injected with 2  105 IU rhIL-2 on days
0, 2, 4, and 6, and the numbers of NK cells in the
spleens were quantified (Figure 1A). A significant
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Figure 1. IL-2 promoted NK cell numbers, function, and antitumor
effect in vivo. C57BL/6 mice were left untreated (control;-) or given
IL-2 (2  1 05 IU on days 1, 3, 5, and 7 :). Spleens from the mice
were removed on day 8, and the number of CD3-NK1.11 NK cells
were determined (n5 2) (A) and splenocytes from indicated treatment
mice were used in a 4-hour chromium release assay against Yac-1 targets
(n 5 3) (B). Mice undergoing this treatment were challenged on day
0 with 2  105 C1498 cells i.v. and analyzed for survival (n 5 8). *P\
.05 as determined by the log-rank test (C). These data are representa-
tive of 5 experiments.
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ment (P\ .01) was seen, from 2  106 cells to . 5 
106 cells, which correlated with a significant (P \
.01) increase in killing by splenocytes as determined
by a 4-hour chromium release assay against the NK
cell–sensitive Yac-1 tumor targets (Figure 1B). Finally,
the in vivo antitumor effects of IL-2 were determined
by injecting C57BL/6 mice with 2 105 C1498 leuke-
mia cells i.v., and then following the same IL-2 regi-
men as before. The IL-2 therapy promoted a slight
but significant (P\ .05) increase in the survival time
of C1498-bearing C57BL/6 mice (Figure 1C). These
data confirm that IL-2 promoted a modest antitumor
response in vivo that was correlated with both an in-
crease in NK cell numbers and killing by splenocytes.
IL-2 Therapy Resulted in Regulatory T Cell
Expansion
Next, we examined the effects of IL-2 immunother-
apyonCD41CD251Tregexpansion (Figure2). Spleno-
cytes fromC57BL/6mice treated or not treated with the
foregoing IL-2 regimen were analyzed for the effects on
Tregs. The control mice consistently expressed approxi-
mately 10% Foxp31 cells (Figure 2A), and IL-2 therapy
led to an increase in CD41Foxp31 Treg percentage
(Figure 2B), as well as to a significant increase in Treg
numbers (Figure 2C; P \ .01). Most Foxp31 cells
expressed CD25, although expression was low or nega-
tive in some. These findings demonstrate that IL-2
administration enhanced the number and function of
NK cells and also increased the number of Tregs, which
can potentially inhibit NK cell–mediated function.
IL-2 Receptors on NK Cells Did Not Change
After IL-2 Therapy
Our Treg depletion strategy was to use the anti-
CD25 monoclonal antibody (PC61.5.3), but first we
wanted to ensure that murine NK cells were not
expressing CD25. Resting NK cells (CD3-NK1.11)
express the low-affinity IL-2Rb (CD122) but not the
high-affinity IL-2Ra (CD25; Figure 3A). After the ear-
lier IL-2 treatment regimen, although we did see an in-
crease in CD251 cells (Figure 2B), we found no
difference in the levels of CD25 or CD122 onNK cells
(Figure 3B), demonstrating that in vivo IL-2 adminis-
tration did not stimulate up-regulation of the IL-2
receptors. These data demonstrate that co-treatment
with IL-2 and anti-CD25 did not result in the deple-
tion of NK cells in vivo.
In Vivo CD25 Depletion Reduced Treg Numbers
After IL-2 Immunotherapy
Next, we examined the combined effects of IL-2
and anti-CD25 therapy on Tregs. IL-2 was given
as before, and anti-CD25 (clone: PC61.5.3) was100 101 102 103 104
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Figure 2. IL-2 increased Treg percentage and numbers. C57BL/6 mice
were untreated or given IL-2, as described in Figure 1. The percentage of
Foxp31 cells out of total CD41 cells is indicated for untreated mice (A)
and IL-2–treated mice (B). The total CD41Foxp31 cells from control
and IL-2–treated mice (n 5 3) is also shown (C). These data are repre-
sentative of 3 experiments.
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Figure 3. CD25 was not expressed on resting or IL-2–activated NK cells in vivo. C57BL/6 mice were untreated or given IL-2, as described in Figure 1.
Splenocytes were harvested on day 8, and CD25 and CD122 expression was determined on CD3-NK1.11 cells from control mice (A) and IL-2–treated
mice (B) (n 5 3). These data are representative from 2 experiments.given at 1 mg per i.p. injection on days 1, 4, and 7.
Splenocytes were isolated after treatment (day 8), and
Tregs were determined by analyzing the number
(Figure 4A) or the percentage (Figure 4B) of
CD41Foxp31 cells. Treating mice with IL-2 consis-
tently resulted in significant expansion of Tregs
(Figure 4A; P \ .01), whereas treating mice with
anti-CD25 resulted in a partial but significant reduc-
tion in CD41Foxp31 cells (P \ .01). Interestingly,
the combination therapy (IL-21 anti-CD25) resulted
in a nearly identical Treg number (Figure 4A) and per-
centage (Figure 4B) as in the anti-CD25–treated mice;
thus, any expansion of Treg numbers by IL-2 appears
to have been abrogated by anti-CD25 therapy.
To examine the in vivo effect of IL-2 and anti-
CD25 on Treg-mediated regulation of NK cells, we
developed amodel that allows the simultaneous activa-
tion of NK cells and depletion of Tregs. The C57BL/6
mice were treated with IL-2 (2  105 IU/0.2mL i.p.,
days 1, 3, 5, and 7) and anti-CD25 (PC61.5.3, 1 mg/
0.2 mL i.p., days 1, 4, and 7), either alone or in combi-
nation. On day 8, mice were sacrificed, and their sple-
nocytes were examined to detect any direct effects of
IL-2 and/or anti-CD25 on NK cell numbers and
GzmB content. As shown in Figure 1A, IL-2 therapy
was capable of generating a large increase in splenic
NK cells (CD3-NK1.11), whereas anti-CD25 treat-
ment alone did not appear to significantly increase
NK cell numbers. The combination of IL-2 and
anti-CD25 failed to increase NK cell numbers to
a greater extent than IL-2 alone (Figure 5A).
We next examined theGzmB content to determine
whether NK cells in treated mice were activated after
IL-2 and anti-CD25 therapy. GzmB staining of
NK cells was essentially negative in control mice
(Figure 5B), because resting murine NK cells gener-
ally lack GzmB expression. But GzmB levels of
CD3-NK1.11 increased to a similar level after IL-2
administration regardless of the administration ofanti-CD25 antibody (cf. Figures 5C and 5E). As
expected, treatment of mice with anti-CD25 antibody
alone did not produce any increase in GzmB levels
(Figure 5D). The data were analyzed statistically by
grouping mice together and examining the mean fluo-
rescence intensity (MFI) of GzmB (Figure 5F). Similar
data were found on analysis of other activationmarkers
(NKG2D, CD69, CD90.2, CD27, CD11b, Ly49C/I,
and Ly49G2), each of which was increased after IL-2
administration and demonstrated no further increase
after anti-CD25 treatment (data not shown). Analysis
of DX5, known to be a marker of mature NK cells
[22], resulted in equivalent intensity regardless of
treatment (data not shown). These results demonstrate
that overall NK cell numbers or phenotype did not
change with CD25 depletion.
IL-2 Administration Combined with CD25
Depletion Enhanced Tumor Cell Killing in
Long-Term but not Short-Term Tumor Assays
Because we found no changes in the phenotype or
numbers of NK cells using combination therapy, we
tested the NK cells in ex vivo assays to determine their
function. Mice treated with IL-2 and/or anti-CD25
were sacrificed, and their splenocytes were tested in
a 4-hour chromium release assay against Yac-1 targets
(Figure 6A). Although the control mice exhibited low
cytolytic activity, the mice that received IL-2 had
enhanced NK cell function (Figure 6A). The mice re-
ceiving anti-CD25 did not have enhanced killing com-
pared with the control mice, whereas the mice
receiving both IL-2 and anti-CD25 were nearly iden-
tical to those receiving IL-2 alone. These data demon-
strate that depletion of CD251 cells did not enhance
the cytolytic function of NK cells in short-term assays.
To reflect the in vivo situation more accurately, we
used a long-term tumor outgrowth assay to assess NK
cell antitumor function (Figure 6B). In this assay,
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spleen cells in 96-well plates with media containing
1000 IU/mL of IL-2 for up to 4 days, before 10 mL
of the cultured cells was placed into 90 mL of fresh
media lacking IL-2 for an additional 3 days. After the
3 days of culture without IL-2, the cells were pulsed
with tritiated thymidine, and relative cell numbers
were determined by tritiated thymidine incorporation.
The full repertoire of NK cell effector pathways is
available in long-term assays as opposed to chromium
release assays, which generally reflect the short-term
effects of cytolytic granules. Although redundant cyto-
toxic mechanisms to the NK cell are available, we have
previously determined that the C1498 leukemia cell
line is sensitive to perforin, FasL, and Trail [23], and
we have unpublished data showing that these cells
are insensitive to tumor necrosis factor-a and IFN-g
(data not shown). In the tumor outgrowth assay, we
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that were CD41 Foxp31 (n 5 2 or 3 mice per group). Analysis was by
1-way ANOVA with Bonferroni’s posttest. The data are combined from
2 experiments.observed that the mice treated with either IL-2
or anti-CD25 had enhanced antitumor function com-
pared with the control mice (Figure 6B). Importantly,
we found that the mice treated with IL-2 and
anti-CD25 had significantly enhanced antitumor func-
tion compared with those receiving IL-2 alone
(Figure 6B; P\ .01).
To verify that the observed proliferation was from
tumor cells and not effector splenocytes, we replicated
the assay without adding tumor cells to the effector
cells (Figure 6C). In these assays, we found relatively
little tritium incorporation, suggesting that after pas-
sage of the cultured cells into media lacking IL-2,
only the tumor cells incorporated substantial amounts
of 3H-thymidine. Finally, we verified that NK cells,
but not CD81T cells, were responsible for the antitu-
mor effects in the outgrowth assay (Figure 6D). In vivo
depletion ofNK1.11 cells resulted in abrogation of an-
titumor effector function, whereas depletion of CD81
cells produced no change in antitumor function in the
outgrowth assay. The activity of NK cells in the out-
growth assay is predominantly through perforin exo-
cytosis, as verified in Figure 6E, in which activated
wild-type and perforin-deficient NK cells were used.
Although perforin is the predominant mechanism,
there is inhibition of tumor outgrowth from per-
forin-deficient NK cells at increased E:T ratios, dem-
onstrating that NK cells use other mechanisms other
than perforin to inhibit tumors in the outgrowth assay.
These results indicate that concurrent treatment with
IL-2 and anti-CD25 led to enhanced killing of tumor
cells compared with treatment with IL-2 alone.
Importantly, this effect was observed only in the
long-term tumor outgrowth assays, not in the short-
term killing assays.
Depletion of CD251 Cells Combined with NK
Cell Activation Led to Markedly Increased NK
Cell–Mediated Antitumor Effects in Vivo
To determine the effects of Tregs on NK cells, we
evaluated the effect of IL-2 and anti-CD25 on NK cell
antileukemic effects in vivo (Figure 7). Interestingly,
depletion of CD251 cells alone had no affect on the
survival of the leukemia-bearing mice. Consistent
with our previous experiments, the mice treated with
IL-2 led to a slight but statistically significant increase
in survival compared with the control mice (*P\ .05).
But the mice treated with both IL-2 and anti-CD25
antibodies exhibited significantly increased survival
compared with either the control mice (**P\ .01) or
the mice treated with IL-2 alone (**P\ .01). These re-
sults demonstrate that in a leukemia-bearing mouse
model, removal of Tregs alone was not sufficient to in-
crease antitumor effects significantly. Similarly, the
addition of IL-2, which activated NK cells and Tregs,
may have countered its own effects due to the increased
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Figure 6. IL-2 and aCD25 promoted tumor inhibition in long-term but not in short-term assays. C57BL/6 mice were treated with PBS (control;-),
rhIL-2 (2  105 IU, days 0, 2, 4, and 6;:), aCD25 (PC61.5.3, 1 mg, days 0, 3, and 6;;), or rhIL-2 and aCD25 (C) before being sacrificed. Their sple-
nocytes were used in a chromium release assay (A) or a tumor outgrowth assay (B). C, Effector cells used in (B) were plated in the absence of tumor cells
to determine the proliferation of the effector cells. D, Mice undergoing IL-2 and anti-CD25 therapy were untreated or were given anti-NK1.1 or anti-
CD8 antibodies and compared in the outgrowth assay. E, Activated NK cells from wild-type or pfp-/- mice were used in the tumor outgrowth assay.
*P\.01. Statistical analysis was performed using 2-way ANOVA with a Bonferroni multiple-comparison test.activation of Tregs, which may have masked increases
in NK cell activation. But the combination of IL-2 and
anti-CD25 allowed activation of NK cells while the in-
hibitory Tregs were removed. This combined therapy
allowed for synergistic increases in survival of the leu-
kemia-bearing mice. Depletion of NK cells from the
mice using anti-NK1.1 antibody in addition to the
combination therapy abrogated all effects on survival
(Figure 7; IL-2 1 aCD25 1 aNK1.1). These data
demonstrate that neither activation of NK cells nor
removal of Tregs alone were sufficient to generate
an optimal antileukemic response; however, the com-
bination therapy promoted powerful antileukemic
responses in functions mediated by NK cells, as
supported by the in vitro tumor outgrowth data.
IL-2 Therapy Combined with CD25 Depletion
Promoted Antitumor Effects Mediated by
NK1.11 Cells but not by CD81 Cells
To verify that our effect was mediated by NK cells
and not by T cells, we compared the effects ofdepleting NK and CD8 T cells (Table 1). Because
CD8 T cells can acquire cytotoxic activity after IL-2
treatment [24] treatment and can up-regulate NK1.1
expression after activation [25], we wanted to ensure
that the effect of our depletion was not dependent on
the loss of activated CD81 T cells. Mice received ei-
ther the IL-2 and anti-CD25 therapy as before or the
therapy with NK1.11 depletion or CD81 depletion.
The mice that received the therapy in combination
withNK1.11 depletion exhibited complete abrogation
of the effect, whereas depletion of CD81 cells did not
influence the therapy. The mice depleted of CD81 T
cells exhibited a 98% reduction in the number of
splenic CD81T cells (data not shown). These data in-
dicate that NK cells, not CD81 T cells, mediated the
antitumor effects of IL-2 and anti-CD25 therapy.
DISCUSSION
Our findings demonstrate that previous depletion
of Tregs together with IL-2 administration led to
1096 Biol Blood Marrow Transplant 14:1088-1099, 2008W. H. D. Hallett et al.synergistic NK cell–mediated antileukemic effects
greater than those from either therapy alone. The ef-
fect of this therapy in vivo was mediated by NK cells,
but not by CD81 T cells. Interestingly, classical,
short-term NK cell killing assays did not demonstrate
increases in NK cell function by combination therapy,
and it was only through long-term tumor outgrowth
assays that we could see enhanced splenocyte function
in the combination-treated mice. These effects were
correlated with in vivo survival. These data are similar
to those from our previous study, which also demon-
strated augmentation of NK cell antitumor effects
with bortezomib only in long-term assays and not in
short-term killing assays, which tend to rely on per-
forin/granzyme lysis [23]. Insight into the mechanism
by which Tregs suppress NK cells has been elusive.
Some studies have suggested that surface-bound trans-
forming growth factor (TGF)-b on the Tregs is
0 10 20 30 40 50 60 70
0
10
20
30
40
50
60
70
80
90
100
rIgG/PBS
αNK1.1
IL-2
αCD25
IL-2 + αCD25
IL-2 + αCD25 + αNK1.1
*
**
Days
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
Figure 7. IL-2 therapy combined with CD25 depletion resulted in sig-
nificant increase in survival compared with IL-2 alone. Mice were in-
jected with 2 105 C1498 cells i.v. on day 0. The mice were injected
with PBS/rIgG controls, with IL-2 (2 105 IU on days 1, 3, 5, and 7),
with anti-CD25 antibodies (1 mg on days 1, 4, and 7), with IL-2 and
anti-CD25 as above, or with IL-2 and anti-CD25 combined with anti-
NK1.1 (500 mg on days 1 and 5). n 5 8 mice per group. *P\.05 com-
pared with rIgG/PBS. **P\.01 compared with either rIgG/PBS or IL-2
alone. These data are combined from 2 experiments.responsible for the inhibition of NK cells [13,14],
whereas others have demonstrated that perforin and
GzmB from Tregs are responsible for inhibiting NK
cells [26]. Studies performed in our laboratory using
purified Tregs and NK cells consistently found no
suppression in short-term killing assays and only
equivocal suppression in long-term outgrowth assays,
regardless of the activation status of the 2 populations
(data not shown). It also is possible that Treg-mediated
suppression of NK cells may involve an as-yet un-
identified third party. We also hypothesize that
Treg-mediated inhibition of NK cells in vivo is associ-
ated with the relative numbers of the 2 populations.
The ratio of Tregs to NK cells in mice at rest is
1:1. Administration of IL-2 expands both cell popu-
lations, keeping the ratio close, whereas anti-CD25 se-
lectively reduces the Treg population, skewing the
ratio toward the NK cells, although the NK cells re-
main inactivated. The combined administration of
IL-2 and anti-CD25 contracts Tregs while expanding
and activating NK cells, resulting in significant skew-
ing toward NK cells. These activated NK cells are
then capable of mediating antitumor effects. Even
though the original article examining the suppression
of NK cells by Tregs was published several years ago
[13], we still do not have an understanding of the
mechanism of Treg-mediated suppression onNK cells
using in vitro assays, possibly due to pleiotropic mech-
anisms of action or assays used for readout.
Recent studies have described a role for Tregs in
the suppression of NK cells both in vivo and in vitro
[13-15]; however, in both of these studies, the mecha-
nism of NK cell inhibition appeared to involve the
down-regulation of NKG2D on the NK cells. Cytoly-
sis of theC1498 (H2b) tumor cell line was not inhibited
by anti-NKG2D antibodies, although cytolysis of the
renal cell carcinoma RENCA (H2d) was inhibited,
which is consistent with NK cell recognition of these
tumors (data not shown) [27]. Therefore, NKG2D
down-regulation is unlikely to be the mechanism by
which Tregs inhibit NK cells in the C1498 leukemia
model.
Other studies have demonstrated that transfer
of wild-type Tregs, but not TGF-b-/- Tregs, intoTable I. IL-2 Therapy Combined with CD25 Depletion Promoted Survival Mediated by NK1.1+ Cells but not CD8+ Cells
Treatment Mice Surviving on Day 35 Mean Survival Time (Mean ± SEM)
Control (no treatment) 0/16 27.1 ± 0.73
rhIL-2 + anti-CD25 8/16* 39.2 ± 3.4†
NK1.1 depletion 0/16 25.0 ± 0.78
NK1.1 depletion + rhIL-2 + anti-CD25 0/16 25.8 ± 0.73
CD8 depletion 0/16 29.1 ± 0.75
CD8 depletion + rhIL-2 + anti-CD25 8/16* 43.8 ± 4.9†
Note. Mice were injected with 2 105 C1498 cells i.v. on day 0. Mice were injected with PBS/rIgG controls; with rhIL-2 (2 105 IU; days 1, 3, 5, and 7)
and anti-CD25 antibodies (1 mg; days 1, 4, and 7); with PK136 (500 ug; days 1 and 5); with rhIL-2 and anti-CD25 as above plus PK136; with anti-CD8 (300
mg; days 1 and 5); or with rhIL-2 and anti-CD25 combined with anti-CD8.
*P < .01 by 2-tailed Fisher’s exact test compared with specific no treatment controls.
†P < .01 by 1-way ANOVA with Tukey’s multiple-comparison test compared with specific no treatment controls.
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pressed NK cell–mediated cytotoxicity [13]. Adoptive
transfer of activatedTregs into tumor-bearing athymic
nudemice was correlated with decreased lungmetasta-
ses of the NKG2D-sensitive tumor cell line, B16-Rae,
but not the untransfected cell line B16. This same
study found an increased proliferation of lymph
node–resident NK cells, as measured by BrdU incor-
poration, followed by depletion of CD251 cells with
the PC61 antibody [13].
In contrast, our data demonstrated no increase in
NK cell numbers after depletion of CD251 cells,
even though we used more than 3 times more PC61
antibody than was used in the previous study.
Although we did not examine at BrdU incorporation
of lymph node–resident NK cells, these differences
may be associated with mouse colony discrepancies,
which may alter NK cell or Treg activation.
A previous study examined a murine model of
colon adenocarcinoma used IL-2 and anti-CD25 im-
munotherapy [28]. Using an intrasplenic injection
model, which led to tumor growth in the liver, the in-
vestigators found that IL-2 and anti-CD25 therapy led
to a decrease in liver weight, presumably through the
reduction of the tumor in the liver. The investigators
then used an IL-2– transfected cell line and injected
these tumors subcutaneously. In these studies, treat-
ment of mice with anti-CD25 reduced tumor growth,
but when contrasted with our study, the effect of treat-
ment was completely abrogated by CD81 depletion
and unaffected by NK1.11 depletion. This difference
may be due to tumor type or route of administration,
and supports the idea that additional benefits can be
obtained by combination therapy.
The removal of Tregs has important clinical ram-
ifications. Methods of removing CD251 cells, includ-
ing using the anti-CD25 monoclonal antibodies
daclizumab and basiliximab, are under study for the re-
moval of Tregs clinically. Denileukin diftitox (IL-2
conjugated to diphtheria toxin) has been approved
for the depletion of Tregs [29] and has been demon-
strated to remove Tregs in patients with ovarian
cancer [30], renal cancer [31], and melanoma [32]. A
potential problem with using anti-CD25 antibodies
clinically is that the expression of CD25 does not ap-
pear to be as correlative on humanTregs as it is onmu-
rine Tregs. Populations of human Tregs have been
shown to lack expression of CD25; thus, removing
these cells using anti-CD25 antibodies may be prob-
lematic [33,34]. But the complete removal of Tregs
may not be necessary for clinical efficacy; partial re-
moval, as in the present study, may be sufficient to
augment immunotherapy.
Depletion of murine Tregs with anti-CD25 is
problematic. Treatment of mice with anti-CD25 was
found to result in the functional inactivation, but not
depletion, of Tregs [35]. These studies are controver-sial, however. Subsequent studies have demonstrated
that partial depletion of Foxp31 Tregs occurred after
treatment with PC61 but not with 7D4, as analyzed
by flow cytometry [36,37]. Our study, in agreement
with previous studies, demonstrates that less than
half of the splenic Foxp31 Tregs were depleted by
anti-CD25 therapy [37]. If the remaining Tregs are
functionally inactive, then the combined effect may
equal that of complete depletion.
Previous reports have examined the clinical use of
IL-2 to activateNK cells in vivo. Interestingly, a subse-
quent clinical study demonstrated that IL-2 adminis-
tration did not express significant levels of CD25,
but did up-regulate CD122 on NK cells [38]. Another
clinical study examined the effects of long-term, low-
dose IL-2 administration in patients who had under-
gone either autologous or T cell–depleted allogeneic
bone marrow transplantation [39]. All patients who
underwent IL-2 therapy had increased NK cell num-
bers and well as cytotoxic function and experienced
minimal toxicity [39]. These studies support the use
of IL-2 to augment NK cell function in clinical thera-
pies, yet the administration of IL-2 has previously been
shown to expand Tregs both clinically [40] and in
murine models [41].
The use of IL-15 instead of IL-2 to activate NK
cells also may be of interest. Resting Tregs express
the high-affinity IL-2 receptor complex [42] and thus
have 100 times more affinity for IL-2 [43] than NK
cells, which generally express the intermediate-affinity
IL-2 receptor complex [44]. Therefore, after IL-2 ad-
ministration,Tregsmaybe capable of activating and re-
spondingmore quickly than other cells. A clinical study
in which ultra–low-dose IL-2 was administered to pa-
tients with human immunodeficiency virus found that
Tregs expanded3 timesmore thanNKcells, suggesting
that Tregs may be more capable of responding to IL-2
[45]. The use of IL-15, which is still capable of activat-
ingTregs [46], should reduce the inherent advantage of
Tregs to respond to IL-2 to a greater extent than cells
lacking the high-affinity IL-2 receptor complex.
In the present study, we found that Treg depletion
with concurrent cytokine-mediated NK cell activation
can have powerful antileukemic effects. This suggests
that our combined therapy may have broad applica-
tions and may have the potential for use in various
antitumor therapies. Further studies investigating the
mechanisms of Treg inhibition of NK cells are ongo-
ing to gain insight into how to optimize and extend this
potential antitumor approach.
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